Citation Impact
Citing Papers
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus
2015 StandoutNatureNobel
Current progress in development of hepatitis C virus vaccines
2013
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial
2005 Standout
Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen–positive chronic hepatitis B
2015
Management of hepatitis B
2007
Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine
2014
Entecavir for Patients with Hepatitis B Decompensated Cirrhosis in China: a meta-analysis
2016
Cancer Statistics, 2021
2021 Standout
Entecavir treatment in kidney transplant recipients infected with hepatitis B
2014
A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C
2003 Standout
Treatment predictors of a sustained virologic response in hepatitis B and C
2008
Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts
2011
American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
2014
A Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD) and Entecavir Treatment for Hepatitis B "e" Antigen-Positive Chronic Hepatitis B
2014
Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis
2013
A view on drug resistance in cancer
2019 StandoutNature
Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA
2014
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B
2008
A robust cell culture system supporting the complete life cycle of hepatitis B virus
2017 StandoutNobel
Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function†
2009
Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection
2016
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Hepatitis B: Reflections on the current approach to antiviral therapy
2008
Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis
2016
Reduction of Infectivity in Chronic Hepatitis B Virus Carriers among Healthcare Providers and Pregnant Women by Antiviral Therapy
2014
Transforming Growth Factor-β Signaling in Immunity and Cancer
2019 Standout
Hepatitis B Virus Infection
2008
New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus
2016
Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis
2009
Hepatitis B viruses: Reverse transcription a different way
2008
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update
2008
Converting Cancer Therapies into Cures: Lessons from Infectious Diseases
2012
Mortality, Liver Transplantation, and Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B Treated With Entecavir vs Lamivudine
2014
Hepatitis C vaccine: supply and demand
2008
Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial)
2014
Efficacy of entecavir treatment for lamivudine‐resistant hepatitis B over 3 years: Histological improvement or entecavir resistance?
2009
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #
2009
Progress in the development of preventive and therapeutic vaccines for hepatitis C virus
2011
Hepatitis B virus infection
2009 Standout
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
2018 Standout
Hepatitis B cure: From discovery to regulatory approval
2017
American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
2014
Cancer stem cells revisited
2017 Standout
Chemoimmunotherapy: reengineering tumor immunity
2013
Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B
2006
Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
2006
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
2004 Standout
New and experimental therapies for HCV
2009
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
The RNA Sensor RIG-I Dually Functions as an Innate Sensor and Direct Antiviral Factor for Hepatitis B Virus
2014 StandoutNobel
Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti‐viral activity of clevudine for 12 weeks in patients with chronic hepatitis B
2008
Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H
2007
Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B
2010
Response to Higher Dose of Entecavir 1.0 mg Daily in Patients With Partial Response to Entecavir 0.5 mg Daily
2012
Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B
2013
Management of treatment failure in chronic hepatitis B
2012
Factors That Predict Response of Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B to Peginterferon-Alfa
2009
Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients
2012
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
2006 Standout
Chronic hepatitis B
2007 Standout
Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment‐naive patients
2007
Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B
2007
Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B
2016
Chronic hepatitis B: Update 2009 #
2009 Standout
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Emerging Biological Principles of Metastasis
2017 Standout
Early hepatitis B virus DNA reduction in hepatitis B e antigen–positive patients with chronic hepatitis B
2008
Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy
2008
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
EMT: 2016
2016 Standout
Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside‐naïve HBeAg‐positive patients with chronic hepatitis B
2009
Then and now: The progress in hepatitis B treatment over the past 20 years
2014
Comparison of the Efficacy of Lamivudine Plus Adefovir Versus Entecavir in the Treatment of Lamivudine-Resistant Chronic Hepatitis B: A Systematic Review and Meta-Analysis
2013
Oxidative Stress in Cancer
2020 Standout
Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines
2013
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
2010 Standout
Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B
2007
CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus
2015 StandoutNobel
Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer
2017 Standout
Clinical Relevance of Minimal Residual Viremia during Long-Term Therapy with Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B
2013
Efficacy of Entecavir Treatment for up to 5 Years in Nucleos(t)ide-Naïve Chronic Hepatitis B Patients in Real Life
2013
Genomic Analysis Reveals a Potential Role for Cell Cycle Perturbation in HCV-Mediated Apoptosis of Cultured Hepatocytes
2009 StandoutNobel
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
2012 Standout
Statins and hepatic steatosis: Perspectives from the Dallas Heart Study
2006
Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study
2014
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B
2008
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies
2007
The Biology of CRISPR-Cas: Backward and Forward
2018 StandoutNobel
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA
2016 StandoutNobel
The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients
2008
Sustained Hepatitis B e Antigen Seroconversion in Patients with Chronic Hepatitis B after Adefovir Dipivoxil Treatment: Analysis of Precore and Basal Core Promoter Mutants
2008
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir
2015
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
AASLD guidelines for treatment of chronic hepatitis B
2015
A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer
2019
Antiviral Combination Therapy for Treatment of Chronic Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus Infection
2008
Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance
2013
Entecavir Exhibits Inhibitory Activity against Human Immunodeficiency Virus under Conditions of Reduced Viral Challenge
2008
Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections
2010
Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus‐related decompensated cirrhosis
2011
Recombinant Hepatitis C Virus Envelope Glycoprotein Vaccine Elicits Antibodies Targeting Multiple Epitopes on the Envelope Glycoproteins Associated with Broad Cross-Neutralization
2014 StandoutNobel
Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems
2014 StandoutNobel
The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic
2015
Broadly Neutralizing Immune Responses against Hepatitis C Virus Induced by Vectored Measles Viruses and a Recombinant Envelope Protein Booster
2012 StandoutNobel
Present and future therapies of hepatitis B: From discovery to cure
2015
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
New insights into the role of EMT in tumor immune escape
2017
Hepatitis B virus core‐related antigen as a surrogate marker for covalently closed circular DNA
2016
Entecavir vs Lamivudine for Prevention of Hepatitis B Virus Reactivation Among Patients With Untreated Diffuse Large B-Cell Lymphoma Receiving R-CHOP Chemotherapy
2014
CRISPR-Cas: biology, mechanisms and relevance
2016 StandoutNobel
Suboptimal Response to Adefovir Dipivoxil Therapy for Chronic Hepatitis B in Nucleoside-Naive Patients is not due to Pre-Existing Drug-Resistant Mutants
2008
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease
2010
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial
2015
Progressive engineering of a homing endonuclease genome editing reagent for the murine X-linked immunodeficiency locus
2014 StandoutNobel
Screening for Hepatitis C Virus Infection in Adolescents and Adults
2020
Approved Antiviral Drugs over the Past 50 Years
2016
Inhibition of Hepatitis B Virus Polymerase by Entecavir
2007
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines
2016
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
2020 Standout
devRS, an autoregulated and essential genetic locus for fruiting body development in Myxococcus xanthus
1993
Review article: long‐term safety of nucleoside and nucleotide analogues in HBV ‐monoinfected patients
2016
Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus
2014 StandoutNobel
Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US – the ENUMERATE study
2015
The generation and analysis of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic
2015
RNA editing of hepatitis B virus transcripts by activation-induced cytidine deaminase
2013 StandoutNobel
The Tumor Microenvironment Innately Modulates Cancer Progression
2019 Standout
Hepatitis B Virus Replication and Liver Disease Progression: The Impact of Antiviral Therapy
2006
Targeted DNA Mutagenesis for the Cure of Chronic Viral Infections
2012
Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysis
2015
Role of Scavenger Receptor Class B Type I in Hepatitis C Virus Entry: Kinetics and Molecular Determinants
2009 StandoutNobel
Works of David Apelian being referenced
Combination Therapy with a Second-Generation Androgen Receptor Antagonist and a Metastasis Vaccine Improves Survival in a Spontaneous Prostate Cancer Model
2013
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma
2013
Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: A randomized study
2014
Phase II Study of the GI-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V Mutation
2014
Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses
2011
Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells
2011
A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B
2006
Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins
2006
2006 GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN SIGNIFICANTLY IMPROVES VIROLOGIC RESPONSE AND ALT NORMALIZATION AT END-OF-TREATMENT AND IMPROVES SVR24 COMPARED TO PEG-IFN/RIBAVIRIN IN GENOTYPE-1 CHRONIC HCV PATIENTS
2010
627 GI-5005 IMMUNOTHERAPY PLUS PEG-IFN/RIBAVIRIN VERSUS PEG-IFN/RIBAVIRIN IN GENOTYPE 1 CHRONIC HCV SUBJECTS; PRELIMINARY PHASE 2 EVR ANALYSES
2009
Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine
2013
Development-specific sigma-factor essential for late-stage differentiation of Myxococcus xanthus.
1990